Skip to main content

Table 2 Characteristics of patients receiving TSC and placebo

From: Treatment of migraines with Tianshu capsule: a multi-center, double-blind, randomized, placebo-controlled clinical trial

CharacteristicsTSC (N = 750)Placebo (N = 250)P values
Age, mean ± SD, y47.59 ± 11.8647.82 ± 12.840.5957
Height, mean ± SD, cm165.81 ± 6.89165.61 ± 7.350.4332
Weight, mean ± SD, Kg63.89 ± 9.3263.57 ± 9.750.5717
Sex (%)Male277 (36.9%)85 (34.0%)0.4018
Female473 (63.1%)165 (66.0%)
Ethnic (%)Han745 (99.3%)248 (99.2%)1.0000
Others5 (0.7%)2 (0.8%)
Marital status (%)Yes714 (95.2%)238 (95.2%)1.0000
No36 (4.8%)12 (4.8%)
Profession (%)Physical149 (19.9%)52 (20.8%)0.7505
Non-physical601 (80.1%)198 (79.2%)
Women of child-bearing age (%)Yes221 (46.7%)81 (49.1%)0.5999
No252 (53.3%)84 (50.9%)
Menstrual cycle, mean ± SD, d28.60 ± 2.4728.56 ± 2.230.5932
Menstrual period, mean ± SD, d5.25 ± 1.375.70 ± 1.480.0114
Diagnosis, no. (%)Migraine with aura200 (26.7%)58 (23.2%)0.2742
Migraine without aura550 (73.3%)192 (76.8%)
Headache attacks during the 3 months before screening period, mean ± SD, no.8.81 ± 2.228.76 ± 2.330.7412
Allergic history, no. (%)Yes22 (2.9%)3 (1.2%)0.1012
No728 (97.1%)247 (98.8%)
Past medical history, no. (%)Yes57 (7.6%)22 (8.8%)0.5468
No693 (92.4%)228 (91.2%)
Use of headache treatment drugs, no. (%)Yes310 (41.3%)103 (41.2%)0.9704
No440 (58.7%)147 (58.8%)
With other diseases, no. (%)Yes54 (7.2%)25 (10.0%)0.1652
No696 (92.8%)225 (90.0%)
  1. d day, no. number, SD Standard deviation, y years